Peptides for the treatment of SARS-COV, pulmonary hypertension, and other pulmonary vascular diseases
Recombinant polypeptides targeting APN inhibit its activity, effectively addressing the limitations of current PAH and SARS-COV treatments by reversing disease progression and reducing smooth muscle proliferation, providing a novel therapeutic strategy for PAH and viral infections.
Patent Information
- Application Number
- PCT/US2024/030970
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-24
- Filing Date
- 2024-05-24
- Publication Date
- 2024-11-28
AI Technical Summary
Current treatments for pulmonary arterial hypertension (PAH) and viral infections like SARS-COV are limited by the subjective nature of data analysis and the need for effective therapeutic strategies targeting initial disease stages, with existing methods being time-consuming and labor-intensive, and lacking in early-stage vascular remodeling understanding.
Development of recombinant polypeptides with at least 80% identity to specific sequences (SEQ ID NO: 1-4) that inhibit aminopeptidase N (APN) to treat SARS-COV and pulmonary vascular diseases by binding to the intracellular portion of APN, potentially reversing disease progression and reducing smooth muscle proliferation.
The APN blocking peptides significantly control right ventricular hypertrophy, reverse vascular changes, and demonstrate potential in mitigating PAH progression, offering a promising therapeutic approach for early-stage treatment of PAH and viral infections.
Smart Images

Figure US2024030970_28112024_PF_FP_ABST
Abstract
Description
PEPTIDES FOR THE TREATMENT OF SARS-COV, PULMONARY HYPERTENSION, AND OTHER PULMONARY VASCULAR DISEASESThis application claims the benefit of U.S. Provisional Application No. 63 / 468,753, filed May 24, 2023, the entire contents of which are hereby incorporated by reference.FIELD OF THE INVENTION
[0001] The present invention is directed to peptides that interrupt the action of APN (aminopeptidase N peptide) for the treatment of, for example, viral infections (e.g., Covid) and pulmonary arterial hypertension (PAH). The interruption is accomplished by binding an antagonist / inhibitor (e.g., peptide, antibody, small molecule) to the intracellular portion of the APN.SEQUENCE LISTING
[0002] The instant application contains a Sequence Listing which has been submitted electronically in XML format and is hereby incorporated by reference in its entirety. Said XML copy, created on May 16, 2024, is named 000259-00300_SL.xml and is 4300 bytes in size.BACKGROUND OF THE INVENTION
[0003] Pulmonary arterial hypertension (PAH) is a deadly cardiovascular disease with 50% of patients facing mortality within 5 years of diagnosis. The disease is characterized by severe thickening of the pulmonary arteries due to uncontrolled proliferation of the smooth muscle cells. That leads to Right Ventricular (RV) hypertrophy and failure. Recently, it was discovered that a protein, Aminopeptidase N (APN) was involved in the pathology of the disease (Yuan, C., et al.). Furthermore, we also designed a peptide drug to target the causal protein and mitigate the disease progression. Preliminary data from our studies show that the APN blocking peptide significantly controlled RV hypertrophy and reversed vascular changes. Efficient development of this peptide as a therapeutic for the early stages in PAH disease would have a huge impact in reversing PAH.
[0004] Although a variety of flow cytometry software analysis methods exist that allow for manual gating and semi-automated analysis, their limitations lie in the subjective nature of human biased analysis that can be difficult to reproduce. Additionally, batch analysis of multipleexperiments using conventional software, can be time consuming as it requires manual adjustments of gating strategies for each experiment due to antibody staining variations. For time-course and multiplexed experiments, the data analysis becomes even more tedious and labor-intensive as it requires an extra gating strategy to demultiplex the barcoded samples.
[0005] Although the end stages of PAH are well characterized, the initial stages that trigger vascular remodeling are yet to be elucidated and are critical in establishing effective therapeutic strategies. There is therefore a need for an effective treatment in the field.SUMMARY OF THE INVENTION
[0006] Some embodiments of the present invention are directed towards a recombinant polypeptide that inhibits aminopeptidase N peptide comprising a polypeptide having at least 80% identity to the polypeptide sequence SEQ ID NO: 1.
[0007] Some embodiments of the present invention are directed towards a recombinant polypeptide that inhibits aminopeptidase N peptide comprising a polypeptide having at least 80% identity to the polypeptide sequence SEQ ID NO: 2.
[0008] Some embodiments of the present invention are directed towards a recombinant polypeptide that inhibits aminopeptidase N peptide comprising a polypeptide having at least 80% identity to the polypeptide sequence SEQ ID NO: 3.
[0009] Some embodiments of the present invention are directed towards a recombinant polypeptide that inhibits aminopeptidase N peptide comprising a polypeptide having at least 80% identity to the polypeptide sequence SEQ ID NO: 4.
[0010] In some embodiments of the present invention, a recombinant polypeptide sequence is administered for the treatment of SARS-COV or pulmonary vascular disease.
[0011] In some embodiments of the present invention, a recombinant polypeptide sequence having at least 80% identity to the polypeptide sequence SEQ ID NO: 1 is administered for the treatment of SARS-COV or pulmonary vascular disease.
[0012] In some embodiments of the present invention, a recombinant polypeptide sequence having at least 80% identity to the polypeptide sequence SEQ ID NO: 2 is administered for the treatment of SARS-COV or pulmonary vascular disease.
[0013] In some embodiments of the present invention, a recombinant polypeptide sequence having at least 80% identity to the polypeptide sequence SEQ ID NO: 3 is administered for the treatment of SARS-COV or pulmonary vascular disease.
[0014] In some embodiments of the present invention, a recombinant polypeptide sequence having at least 80% identity to the polypeptide sequence SEQ ID NO: 4 is administered for the treatment of SARS-COV or pulmonary vascular disease.
[0015] Some embodiments of the present invention are directed towards a method of treating SARS-COV, pulmonary vascular disease, or viral infection by administering a pharmaceutically effective amount of a recombinant polypeptide that inhibits aminopeptidase N peptide.
[0016] Some embodiments of the present invention are directed towards a method of treating a viral infection (such as SARS-COV), or a pulmonary vascular disease (such as pulmonary arterial hypertension), by administering a pharmaceutically effective amount of a recombinant polypeptide that inhibits aminopeptidase N peptide comprising a polypeptide having at least 80% identity to the polypeptide sequence SEQ ID NO: 1.
[0017] Some embodiments of the present invention are directed towards a method of treating viral infection (such as SARS-COV), or a pulmonary vascular disease (such as pulmonary arterial hypertension)by administering a pharmaceutically effective amount of a recombinant polypeptide that inhibits aminopeptidase N peptide comprising a polypeptide having at least 80% identity to the polypeptide sequence SEQ ID NO: 2.
[0018] Some embodiments of the present invention are directed towards A method of treating viral infection (such as SARS-COV), or a pulmonary vascular disease (such as pulmonary arterial hypertension)by administering a pharmaceutically effective amount of a recombinant polypeptide that inhibits aminopeptidase N peptide comprising a polypeptide having at least 80% identity to the polypeptide sequence SEQ ID NO: 3.
[0019] Some embodiments of the present invention are directed towards a method of treating viral infection (such as SARS-COV), or a pulmonary vascular disease (such as pulmonary arterial hypertension)by administering a pharmaceutically effective amount of a recombinant polypeptide that inhibits aminopeptidase N peptide comprising a polypeptide having at least 80% identity to the polypeptide sequence SEQ ID NO: 4.
[0020] Some embodiments of the present invention are directed towards a recombinant polypeptide that inhibits aminopeptidase-N.
[0021] In some embodiments, a recombinant peptide that inhibits aminopeptidase-N is administered for the treatment viral infection (such as SARS-COV), or a pulmonary vascular disease (such as pulmonary arterial hypertension).BRIEF DESCRIPTION OF THE DRAWINGS
[0022] FIG. 1 is an image of western blots showing APN in the lungs of PAH patients and genetic animal models of PAH.
[0023] FIG. 2 displays images of fluorescent microscope where the mitochondria associates with APN at the membrane.
[0024] FIG. 3 is bar graph of proteomics demonstrating that APM is associated with several mitochondrial proteins.
[0025] FIG. 4 is a bar graph documenting how APN blocking peptide (B-APN4) peptide significantly prevents the progression of PAH in the NFU1 PAH rats through measurement of right ventricular systolic pressure.
[0026] FIG. 5 is a chart documenting how APN blocking peptide (B-APN4) peptide significantly prevents the progression of PAH in the NFU1 PAH rats through measurement of pulmonary acceleration time on Echo.
[0027] FIG. 6 is a schematic illustration of how targeting APN signaling domains control cell proliferation and a strategy to control PAH through APN signal domain blocking.DETAILED DESCRIPTION OF THE INVENTION
[0028] It is to be noted that the term "a" or "an" entity refers to one or more of that entity.
[0029] As such, the terms "a" (or "an"), "one or more," and "at least one" can be used interchangeably herein. It is further noted that the claims can be drafted to exclude any optional element. As such, this statement is intended to serve as antecedent basis for use of such exclusive terminology as "solely," "only" and the like in connection with the recitation of claim elements, or use of a negative limitation.
[0030] Furthermore, "and / or" where used herein is to be taken as specific disclosure of each of the two specified features or components with or without the other. Thus, the term and / or" as used in a phrase such as "A and / or B" herein is intended to include "A and B," "A or B," "A" (alone), and "B" (alone). Likewise, the term "and / or" as used in a phrase such as "A, B, and / or C" is intended to encompass each of the following aspects: A, B, and C; A, B, or C; A or C; A or B; B or C; A and C; A and B; Band C; A (alone); B (alone); and C (alone).
[0031] It is understood that wherever aspects are described herein with the language "comprising," otherwise analogous aspects described in terms of "consisting of and / or "consisting essentially of are also provided.
[0032] The term “subject” or “patient” as used herein refers to either a human or a non-human animal. These terms include mammals such as humans, primates, livestock animals (e.g., bovines and porcines), companion animals (e.g., canines and felines) and rodents (e.g., mice and rats).
[0033] As used herein, the term “about” when appearing before a range should be understood as referring to both endpoints of the range. In such instances the range should also be understood as including the range defined by the specific endpoints listed, and also including sub-ranges within the listed endpoints. In the instances where “about’ is appearing before a number it should be understood as the number includes the range of + / - 5%.
[0034] As used herein the term “between” when appearing before a range should be understood as referring to both endpoints of the range. In such instances the range should also be understood as including the range defined by the specific endpoints listed, and also including sub-ranges within the listed endpoints.
[0035] As used herein, the term pharmaceutically effective amount means an amount of a drug, for example, APN polypeptide inhibitors or a pharmaceutically acceptable salt thereof, whichhas a desired effect of reducing, curing or alleviating the disease or its symptoms when administered to the subject in need thereof.
[0036] Some embodiments of the present invention pertain to inhibiting aminopeptidase N peptide (APN). In some instances, APN is inhibited by a peptide. In some instances, APN is inhibited by an antibody. In some instances, APN is inhibited by a small molecule. In some instances, APN is inhibited by a polypeptide. In some instances, the signaling domains of APN are inhibited. In some instances, only one signaling domain of APN is inhibited. In some instances, at least one signaling domain of APN is inhibited. In some instances, the intracellular portion of APN is inhibited. In some instances, the extracellular portion of APN is inhibited. In some instances, the transmembrane portion of APN is inhibited.
[0037] Some embodiments of the present invention pertain to inhibition of APN through a polypeptide. In some instances, the polypeptide comprises a sequence of at least 80%, at least 85%, at least 90%, or at least 95% of SEQ ID NO. 1. In some instances, the polypeptide comprises a sequence of at least 80%, at least 85%, at least 90%, or at least 95% of SEQ ID NO.2. In some instances, the polypeptide comprises a sequence of at least 80%, at least 85%, at least 90%, or at least 95% of SEQ ID NO. 3. In some instances, the polypeptide comprises a sequence of at least 80%, at least 85%, at least 90%, or at least 95% of SEQ ID NO. 4. In some instances, the polypeptide is packaged into a nano particle. In some instances, the polypeptide is packaged into a lipid micelle. In some instances, the polypeptide is delivered as mRNA to be translated in the patient.
[0038] In some embodiments of the present invention, APN is inhibited in a patient. In some instances, the patient has cardiovascular disease. In some instances, the patient has pulmonary arterial hypertension (PAH). In some instances, the patient has a viral infection. In some instances, the viral infection is SAR-COV. In some instances, the viral infection is Covid-19. In some instances, the disease is enriched in APN.
[0039] In some instances, APN inhibition leads to a decrease in disease progression of PAH patients. In some instances, reversing disease progression means a decrease in arterial walls. In some instances, smooth muscle proliferation on arterial walls decreases. In some instances, the measurement of disease regression is through measuring pulmonary artery acceleration time (PAT). In some instances, the measurement of disease regression is through right ventricular systolic pressure.Examples
[0040] Recent studies from our lab have shown that metabolic changes precede PAH and mitochondrial dysfunction (MD) is known to trigger metabolic anomalies (Rafikoca, O., et al., and James J., et al.). A large body of experimental and clinical evidence points to the role of MD in the control of PAH pathophysiology (Cullet, M. K. and S.Y. Chan). Interestingly, 7 out of 10 humans with a mutation in NFU1, a mitochondrial iron sulfur cluster chaperone, develop lethal PAH (Niihori, M., et al.). However, the rate of PAH in the general population is 50 per million (Niihori, M., et al.). That points to the causative role of MD in the induction of PAH. However, the precise mechanisms through which MD triggers PAH are largely unknown. Building on that idea, we developed a rat model with a homologous mutation in NFU1 and found that they spontaneously develop PAH with severe MD and remodeled pulmonary vasculature (Niihori, M., et al.). Interestingly, the increase in MD was accompanied by a severe 40-fold upregulation of APN. Furthermore, we also found a 10-fold increase in APN in the lungs of idiopathic PAH patents through western blot analysis (Fig. 1). Interestingly, APN is implicated in proliferative diseases such as cancer which bears similarities with PAH (Wickstrbm, M., et al.). Preliminary data shows that the novel APN blocking peptide is successfully able to reverse the disease progression in the NFU1 rat PAH model, thus indicating that APN could play a major role in the pathological mechanisms of MD induced PAH.
[0041] Using proteomics and high-resolution imaging revealed that MD induces APN to associate with mitochondrial proteins (Figs. 2-3). Importantly, this interaction with APN could play a pathological regulatory role. Secondly, MD increases the transcription factors that upregulate APN expression. Finally, preliminary data from single cell transcriptomics shows that APN could induce certain cell types to become highly proliferative and therefore contribute to arterial thickening. Thus, we were able to link the pathological function of APN directly to its signaling domains. Using bioinformatic analysis, we designed and synthesized several novel peptides to block various signaling domains of APN.
[0042] The findings identified one domain of APN (domain 4, Fig. 6) in the cytosolic region close to the membrane to bear pathological implications. The initial result of the APN blocking peptide (B-APN4) is outstanding as at a very low dose of 2mg / kg B.W, as the peptide significantly prevents the progression of PAH in the NFU1 PAH rats (Figs 1, 4-5). Fig. 4 measures the right ventricular systolic pressure wherein the delivery of B-APN4 restores thepressure in the right ventricle when compared with wildtype. Fig. 5 measures the ECHO-PAT within the hearts of the rats between NFU1 mutation model and wildtype. Treatment of the NFU1 mutation model with B-APN4 restores the heart to conditions similar to wildtype with measured through ECHO-PAT. In addition to this, preliminary findings show that treatment of this peptide in the isolated smooth muscle cells of the NFU1 rats significantly reduced its growth rate. In comparison with bestatin (a traditional APN inhibitor, targeting the peptidase domain), this peptide is far more efficient for use in experimental PAH. Thus, this innovative strategy is very effective in controlling APN signaling without affecting the peptidase domain as APN is also an essential surface protein.
[0043] Experiments are performed in genetic rat models of PAH and in isolated pulmonary cells, in-vitro. The first set of experiments focus on unraveling the proliferative signaling pathways of APN. To achieve that, APN is immuno-precipitated for studying its associated signaling proteins using proteomics. These proteomics studies yielded the inhibitor polypeptides found in SEQ ID NO: 1-4. The second stage involves studying how the APN peptide blocks its targets in animal models of PAH and in cell culture. The final stage is using various packaging strategies for delivery of the polypeptide inhibitors.
[0044] The impact of this study is two-fold: it shows that APN is a remarkable protein to target in PAH and secondly shows that supplementing the APN blocking peptide for PAH in the early stages could prove to be highly successful in mitigating the progress of this deadly disease.
[0045] Diminishing Aminopeptidase N signaling represents a novel therapeutic approach for addressing pulmonary vascular conditions related to the function or dysfunction of pericytes, smooth muscle cells, and endothelial cells in the arteries and capillaries. This is relevant to various pulmonary vasculopathies and pathologies, encompassing, but not limited to, acute viral infections, pulmonary hypertension, bronchopulmonary dysplasia, and more.
[0046] Peptides that are encoded in accordance with exemplary embodiments of the technology may have at least 80%, 85%, 90%, or preferably 95% identity to the following sequences as seen in Table 1 :Table 1References1. Rafikova, O., et al., Metabolic Changes Precede the Development of PulmonaryHypertension in the Monocrotaline Exposed Rat Lung. PLOS ONE, 2016. 11(3): p. e0150480.2. James, J., et al., Single Mutation in the NFU1 gene metabolically reprograms pulmonary artery smooth muscle cells. Arteriosclerosis, thrombosis, and vascular biology, 2021.41(2): p. 734-754.3. Culley, M.K. and S.Y. Chan, Mitochondrial metabolism in pulmonary hypertension: beyond mountains there are mountains. The Journal of clinical investigation, 2018. 128(9): p. 3704-3715.4. Yuan, C., et al., Protein biomarkers and risk scores in pulmonary arterial hypertensions associated with ventricular septal defect: integration of multi-omics and validation. American Journal of Physiology, Lung Cellular and Molecular Physiology, 2020. 319(5): p. L810-L822.5. Niihori, M., et al., Rats with a human mutation ofNFUl develop pulmonary hypertension.American journal of respiratory cell and molecular biology, 2020. 62(2): p. 231-242.6. Wickstrbm, M., et al., Aminopeptidase N (CD13) as a target for cancer chemotherapy. Cancer science, 2011. 102(3): p. 501-508.
[0047] The foregoing description and drawings should be considered as illustrative only of the principles of the invention. The invention is not intended to be limited by the preferred embodiment and may be implemented in a variety of ways that will be clear to one of ordinary skill in the art. Numerous applications of the invention will readily occur to those skilled in the art. Therefore, it is not desired to limit the invention to the specific examples disclosed or the exact construction and operation shown and described. Rather, all suitable modifications and equivalents may be resorted to, falling within the scope of the invention. All references cited herein are incorporated by reference.
Claims
CLAIMS1. A recombinant polypeptide that inhibits aminopeptidase N peptide comprising a polypeptide having at least 80% identity to the polypeptide sequence SEQ ID NO: 1.
2. A recombinant polypeptide that inhibits aminopeptidase N peptide comprising a polypeptide having at least 80% identity to the polypeptide sequence SEQ ID NO: 2.
3. A recombinant polypeptide that inhibits aminopeptidase N peptide comprising a polypeptide having at least 80% identity to the polypeptide sequence SEQ ID NO: 3.
4. A recombinant polypeptide that inhibits aminopeptidase N peptide comprising a polypeptide having at least 80% identity to the polypeptide sequence SEQ ID NO: 4.
5. The polypeptide of claim 1, wherein the polypeptide is administered for the treatment of SARS-COV or pulmonary vascular disease.
6. The polypeptide of claim 2, wherein the polypeptide is administered for the treatment of SARS-COV or pulmonary vascular disease.
7. The polypeptide of claim 3, wherein the polypeptide is administered for the treatment of SARS-COV or pulmonary vascular disease.
8. The polypeptide of claim 4, wherein the polypeptide is administered for the treatment of SARS-COV or pulmonary vascular disease.
9. A recombinant polypeptide that inhibits aminopeptidase N.
10. The polypeptide of claim 9, wherein the polypeptide is administered for the treatment of SARS-COV or pulmonary vascular disease.
11. A recombinant polypeptide of any one of claims 5-8 and 10, wherein the pulmonary vascular disease is pulmonary arterial hypertension.
12. A method of treating SARS-COV, pulmonary vascular disease, or viral infection in a patient in need thereof comprising administering to the patient a pharmaceutically effective amount of a recombinant polypeptide that inhibits aminopeptidase N peptide comprising a polypeptide having at least 80% identity to the polypeptide sequence SEQ ID NO: 1.
13. A method of treating SARS-COV, pulmonary vascular disease, or viral infection in a patient in need thereof comprising administering to the patient a pharmaceutically effective amount of a recombinant polypeptide that inhibits aminopeptidase N peptide comprising a polypeptide having at least 80% identity to the polypeptide sequence SEQ ID NO: 2.
14. A method of treating SARS-COV, pulmonary vascular disease, or viral infection in a patient in need thereof comprising administering to the patient a pharmaceutically effective amount of a recombinant polypeptide that inhibits aminopeptidase N peptide comprising a polypeptide having at least 80% identity to the polypeptide sequence SEQ ID NO: 3.
15. A method of treating SARS-COV, pulmonary vascular disease, or viral infection in a patient in need thereof comprising administering to the patient a pharmaceutically effective amount of a recombinant polypeptide that inhibits aminopeptidase N peptide comprising a polypeptide having at least 80% identity to the polypeptide sequence SEQ ID NO: 4.
16. A method of treating SARS-COV, pulmonary vascular disease, or viral infection in a patient in need thereof comprising administering to the patient a pharmaceutically effective amount of a recombinant polypeptide that inhibits aminopeptidase N peptide.
17. A method of any one of claims 13-16, wherein the vascular disease is pulmonary arterial hypertension.
Citation Information
Patent Citations
Carbamido peptide aminopeptidase N inhibitor and application thereof
CN101817769B
Peptide compositions and methods of use thereof for disrupting TEAD interactions
WO2018136614A1
Methods and compositions for treating viral infection
WO2022115536A2
